Literature DB >> 23998444

Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

Chunrong Li1, Toni M Brand, Mari Iida, Shyhmin Huang, Eric A Armstrong, Albert van der Kogel, Deric L Wheeler.   

Abstract

HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. In the present study, we investigated the capacity of the HER3 blocking antibody, U3-1287/AMG888, to modulate the in vitro and in vivo radiation response of human squamous cell carcinomas of the lung and head and neck. We screened a battery of cell lines from these tumors for HER3 expression and demonstrated that all cell lines screened exhibited expression of HER3. Importantly, U3-1287/AMG888 treatment could block both basal HER3 activity and radiation induced HER3 activation. Proliferation assays indicated that HER3 blockade could decrease the proliferation of both HNSCC cell line SCC6 and NSCLC cell line H226. Further, we demonstrated that U3-1287/AMG888 can sensitize cells to radiation in clonogenic survival assays, in addition to increasing DNA damage as detected via λ-H2AX immunofluorescence. To determine if U3-1287/AMG888 could enhance radiation sensitivity in vivo we performed tumor growth delay experiments using SCC6, SCC1483, and H226 xenografts. The results of these experiments indicated that the combination of U3-1287/AMG888 and radiation could decrease tumor growth in studies using single or fractionated doses of radiation. Analysis of HER3 expression in tumor samples indicated that radiation treatment activated HER3 in vivo and that U3-1287/AMG888 could abrogate this activation. Immunohistochemistry analysis of SCC6 tumors treated with both U3-1287/AMG888 and a single dose of radiation demonstrated that various cell survival and proliferation markers could be reduced. Collectively our findings suggest that U3-1287/AMG888 in combination with radiation has an impact on cell and tumor growth by increasing DNA damage and cell death. These findings suggest that HER3 may play an important role in response to radiation therapy and blocking its activity in combination with radiation may be of therapeutic benefit in human tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23998444      PMCID: PMC3901945     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  48 in total

Review 1.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

2.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Authors:  S M Huang; J M Bock; P M Harari
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

4.  Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

Authors:  Prakash Chinnaiyan; Shyhmin Huang; Geetha Vallabhaneni; Eric Armstrong; Sooryanarayana Varambally; Scott A Tomlins; Arul M Chinnaiyan; Paul M Harari
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein.

Authors:  S L Sierke; K Cheng; H H Kim; J G Koland
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

6.  Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2.

Authors:  Lisa-Marie Sturla; George Amorino; Michael S Alexander; Ross B Mikkelsen; Kristoffer Valerie; Rupert K Schmidt-Ullrichr
Journal:  J Biol Chem       Date:  2005-02-11       Impact factor: 5.157

7.  Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

Authors:  Karl-Ludwig Schaefer; Kristin Brachwitz; Yvonne Braun; Raihanatou Diallo; Daniel H Wai; Susanne Zahn; Dominik T Schneider; Cornelius Kuhnen; Arabel Vollmann; Gero Brockhoff; Helmut E Gabbert; Christopher Poremba
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

8.  The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases.

Authors:  Y Devary; R A Gottlieb; T Smeal; M Karin
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

9.  NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.

Authors:  Kristina Buac; Mai Xu; Julie Cronin; Ashani T Weeraratna; Stephen M Hewitt; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2009-07-30       Impact factor: 4.693

10.  UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines.

Authors:  Bhuminder Singh; Matthias Schneider; Pjotr Knyazev; Axel Ullrich
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

View more
  20 in total

1.  Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Authors:  Abhik Bandyopadhyay; Edward Favours; Doris A Phelps; Vanessa Del Pozo; Samson Ghilu; Dias Kurmashev; Joel Michalek; Aron Trevino; Denis Guttridge; Cheryl London; Kenji Hirotani; Ling Zhang; Raushan T Kurmasheva; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2017-10-28       Impact factor: 3.167

2.  MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.

Authors:  Nellie K McDaniel; Christopher T Cummings; Mari Iida; Justus Hülse; Hannah E Pearson; Eleana Vasileiadi; Rebecca E Parker; Rachel A Orbuch; Olivia J Ondracek; Noah B Welke; Grace H Kang; Kurtis D Davies; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Paul M Harari; Randall J Kimple; Deborah DeRyckere; Douglas K Graham; Deric L Wheeler
Journal:  Mol Cancer Ther       Date:  2018-08-09       Impact factor: 6.261

3.  HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Authors:  Megan Jo Miller; Kevin C Foy; Jay P Overholser; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 4.  HER3 in cancer: from the bench to the bedside.

Authors:  Lucía Gandullo-Sánchez; Alberto Ocaña; Atanasio Pandiella
Journal:  J Exp Clin Cancer Res       Date:  2022-10-21

5.  AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Authors:  Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; John P Coan; Hannah E Pearson; Harsh Bahrar; Tyler L Fowler; Bryan P Bednarz; Sandeep Saha; David Yang; Parkash S Gill; Mark W Lingen; Vassiliki Saloura; Victoria M Villaflor; Ravi Salgia; Randall J Kimple; Deric L Wheeler
Journal:  Clin Cancer Res       Date:  2015-03-12       Impact factor: 12.531

6.  Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

Review 7.  Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.

Authors:  Nadège Gaborit; Moshit Lindzen; Yosef Yarden
Journal:  Hum Vaccin Immunother       Date:  2015-11-03       Impact factor: 3.452

8.  Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.

Authors:  Toni M Brand; Mari Iida; Emily F Dunn; Neha Luthar; Kellie T Kostopoulos; Kelsey L Corrigan; Matthew J Wleklinski; David Yang; Kari B Wisinski; Ravi Salgia; Deric L Wheeler
Journal:  Mol Cancer Ther       Date:  2014-03-14       Impact factor: 6.261

9.  AXL mediates resistance to cetuximab therapy.

Authors:  Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; Neha Luthar; Mahmoud Toulany; Parkash S Gill; Ravi Salgia; Randall J Kimple; Deric L Wheeler
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701

10.  AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.

Authors:  Mari Iida; Nellie K McDaniel; Kourtney L Kostecki; Noah B Welke; Carlene A Kranjac; Peng Liu; Colin Longhurst; Justine Y Bruce; Seungpyo Hong; Ravi Salgia; Deric L Wheeler
Journal:  BMC Cancer       Date:  2022-04-23       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.